1 Study Coverage 1.1 Oral Hypoglycemic Drugs Product Introduction 1.2 Market by Type 1.2.1 Global Oral Hypoglycemic Drugs Market Size Growth Rate by Type 1.2.2 Sulfonylureas (SU) 1.2.3 Double Guanidine 1.2.4 Glucosidase Inhibitor 1.2.5 Insulin Synergist 1.3 Market by Application 1.3.1 Global Oral Hypoglycemic Drugs Market Size Growth Rate by Application 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Oral Hypoglycemic Drugs Market Size, Estimates and Forecasts 2.1.1 Global Oral Hypoglycemic Drugs Revenue 2016-2027 2.1.2 Global Oral Hypoglycemic Drugs Sales 2016-2027 2.2 Global Oral Hypoglycemic Drugs, Market Size by Region: 2016 VS 2021 VS 2027 2.3 Oral Hypoglycemic Drugs Historical Market Size by Region (2016-2021) 2.3.1 Global Oral Hypoglycemic Drugs Retrospective Market Scenario in Sales by Region: 2016-2021 2.3.2 Global Oral Hypoglycemic Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021 2.4 Oral Hypoglycemic Drugs Market Estimates and Projections by Region (2022-2027) 2.4.1 Global Oral Hypoglycemic Drugs Sales Forecast by Region (2022-2027) 2.4.2 Global Oral Hypoglycemic Drugs Revenue Forecast by Region (2022-2027) 3 Global Oral Hypoglycemic Drugs Competitor Landscape by Players 3.1 Global Top Oral Hypoglycemic Drugs Manufacturers by Sales 3.1.1 Global Oral Hypoglycemic Drugs Sales by Manufacturer (2016-2021) 3.1.2 Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturer (2016-2021) 3.2 Global Top Oral Hypoglycemic Drugs Manufacturers by Revenue 3.2.1 Key Oral Hypoglycemic Drugs Manufacturers Covered: Ranking by Revenue 3.2.2 Global Oral Hypoglycemic Drugs Revenue by Manufacturers (2016-2021) 3.2.3 Global Oral Hypoglycemic Drugs Revenue Share by Manufacturers (2016-2021) 3.2.4 Global Oral Hypoglycemic Drugs Market Concentration Ratio (CR5 and HHI) (2016-2021) 3.2.5 Global Top 10 and Top 5 Companies by Oral Hypoglycemic Drugs Revenue in 2020 3.2.6 Global Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Oral Hypoglycemic Drugs Price by Manufacturers 3.4 Global Oral Hypoglycemic Drugs Manufacturing Base Distribution, Product Types 3.4.1 Oral Hypoglycemic Drugs Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Oral Hypoglycemic Drugs Product Type 3.4.3 Date of International Manufacturers Enter into Oral Hypoglycemic Drugs Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2016-2027) 4.1 Global Oral Hypoglycemic Drugs Market Size by Type (2016-2021) 4.1.1 Global Oral Hypoglycemic Drugs Sales by Type (2016-2021) 4.1.2 Global Oral Hypoglycemic Drugs Revenue by Type (2016-2021) 4.1.3 Oral Hypoglycemic Drugs Average Selling Price (ASP) by Type (2016-2021) 4.2 Global Oral Hypoglycemic Drugs Market Size Forecast by Type (2022-2027) 4.2.1 Global Oral Hypoglycemic Drugs Sales Forecast by Type (2022-2027) 4.2.2 Global Oral Hypoglycemic Drugs Revenue Forecast by Type (2022-2027) 4.2.3 Oral Hypoglycemic Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) 5 Breakdown Data by Application (2016-2027) 5.1 Global Oral Hypoglycemic Drugs Market Size by Application (2016-2021) 5.1.1 Global Oral Hypoglycemic Drugs Sales by Application (2016-2021) 5.1.2 Global Oral Hypoglycemic Drugs Revenue by Application (2016-2021) 5.1.3 Oral Hypoglycemic Drugs Price by Application (2016-2021) 5.2 Oral Hypoglycemic Drugs Market Size Forecast by Application (2022-2027) 5.2.1 Global Oral Hypoglycemic Drugs Sales Forecast by Application (2022-2027) 5.2.2 Global Oral Hypoglycemic Drugs Revenue Forecast by Application (2022-2027) 5.2.3 Global Oral Hypoglycemic Drugs Price Forecast by Application (2022-2027) 6 Japan by Players, Type and Application 6.1 Japan Oral Hypoglycemic Drugs Market Size YoY Growth 2016-2027 6.1.1 Japan Oral Hypoglycemic Drugs Sales YoY Growth 2016-2027 6.1.2 Japan Oral Hypoglycemic Drugs Revenue YoY Growth 2016-2027 6.1.3 Japan Oral Hypoglycemic Drugs Market Share in Global Market 2016-2027 6.2 Japan Oral Hypoglycemic Drugs Market Size by Players (International and Local Players) 6.2.1 Japan Top Oral Hypoglycemic Drugs Players by Sales (2016-2021) 6.2.2 Japan Top Oral Hypoglycemic Drugs Players by Revenue (2016-2021) 6.3 Japan Oral Hypoglycemic Drugs Historic Market Review by Type (2016-2021) 6.3.1 Japan Oral Hypoglycemic Drugs Sales Market Share by Type (2016-2021) 6.3.2 Japan Oral Hypoglycemic Drugs Revenue Market Share by Type (2016-2021) 6.3.3 Japan Oral Hypoglycemic Drugs Price by Type (2016-2021) 6.4 Japan Oral Hypoglycemic Drugs Market Estimates and Forecasts by Type (2022-2027) 6.4.1 Japan Oral Hypoglycemic Drugs Sales Forecast by Type (2022-2027) 6.4.2 Japan Oral Hypoglycemic Drugs Revenue Forecast by Type (2022-2027) 6.4.3 Japan Oral Hypoglycemic Drugs Price Forecast by Type (2022-2027) 6.5 Japan Oral Hypoglycemic Drugs Historic Market Review by Application (2016-2021) 6.5.1 Japan Oral Hypoglycemic Drugs Sales Market Share by Application (2016-2021) 6.5.2 Japan Oral Hypoglycemic Drugs Revenue Market Share by Application (2016-2021) 6.5.3 Japan Oral Hypoglycemic Drugs Price by Application (2016-2021) 6.6 Japan Oral Hypoglycemic Drugs Market Estimates and Forecasts by Application (2022-2027) 6.6.1 Japan Oral Hypoglycemic Drugs Sales Forecast by Application (2022-2027) 6.6.2 Japan Oral Hypoglycemic Drugs Revenue Forecast by Application (2022-2027) 6.6.3 Japan Oral Hypoglycemic Drugs Price Forecast by Application (2022-2027) 7 North America 7.1 North America Oral Hypoglycemic Drugs Market Size YoY Growth 2016-2027 7.2 North America Oral Hypoglycemic Drugs Market Facts & Figures by Country 7.2.1 North America Oral Hypoglycemic Drugs Sales by Country (2016-2021) 7.2.2 North America Oral Hypoglycemic Drugs Revenue by Country (2016-2021) 7.2.3 U.S. 7.2.4 Canada 8 Asia Pacific 8.1 Asia Pacific Oral Hypoglycemic Drugs Market Size YoY Growth 2016-2027 8.2 Asia Pacific Oral Hypoglycemic Drugs Market Facts & Figures by Region 8.2.1 Asia Pacific Oral Hypoglycemic Drugs Sales by Region (2016-2021) 8.2.2 Asia Pacific Oral Hypoglycemic Drugs Revenue by Region (2016-2021) 8.2.3 China 8.2.4 Japan 8.2.5 South Korea 8.2.6 India 8.2.7 Australia 8.2.8 Australia 8.2.9 Indonesia 8.2.10 Thailand 8.2.11 Malaysia 8.2.12 Philippines 8.2.13 Vietnam 9 Europe 9.1 Europe Oral Hypoglycemic Drugs Market Size YoY Growth 2016-2027 9.2 Europe Oral Hypoglycemic Drugs Market Facts & Figures by Country 9.2.1 Europe Oral Hypoglycemic Drugs Sales by Country (2016-2021) 9.2.2 Europe Oral Hypoglycemic Drugs Revenue by Country (2016-2021) 9.2.3 Germany 9.2.4 France 9.2.5 U.K. 9.2.6 Italy 10 Latin America 10.1 Latin America Oral Hypoglycemic Drugs Market Size YoY Growth 2016-2027 10.2 Latin America Oral Hypoglycemic Drugs Market Facts & Figures by Country 10.2.1 Latin America Oral Hypoglycemic Drugs Sales by Country (2016-2021) 10.2.2 Latin America Oral Hypoglycemic Drugs Revenue by Country (2016-2021) 10.2.3 Mexico 10.2.4 Brazil 10.2.5 Argentina 11 Middle East and Africa 11.1 Middle East and Africa Oral Hypoglycemic Drugs Market Size YoY Growth 2016-2027 11.2 Middle East and Africa Oral Hypoglycemic Drugs Market Facts & Figures by Country 11.2.1 Middle East and Africa Oral Hypoglycemic Drugs Sales by Country (2016-2021) 11.2.2 Middle East and Africa Oral Hypoglycemic Drugs Revenue by Country (2016-2021) 11.2.3 Turkey 11.2.4 Saudi Arabia 11.2.5 UAE 12 Company Profiles 12.1 Pfizer 12.1.1 Pfizer Corporation Information 12.1.2 Pfizer Description and Business Overview 12.1.3 Pfizer Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.1.4 Pfizer Oral Hypoglycemic Drugs Products Offered 12.1.5 Pfizer Recent Development 12.2 AstraZeneca 12.2.1 AstraZeneca Corporation Information 12.2.2 AstraZeneca Description and Business Overview 12.2.3 AstraZeneca Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.2.4 AstraZeneca Oral Hypoglycemic Drugs Products Offered 12.2.5 AstraZeneca Recent Development 12.3 Johnson & Johnson 12.3.1 Johnson & Johnson Corporation Information 12.3.2 Johnson & Johnson Description and Business Overview 12.3.3 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.3.4 Johnson & Johnson Oral Hypoglycemic Drugs Products Offered 12.3.5 Johnson & Johnson Recent Development 12.4 GlaxoSmithKline 12.4.1 GlaxoSmithKline Corporation Information 12.4.2 GlaxoSmithKline Description and Business Overview 12.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.4.4 GlaxoSmithKline Oral Hypoglycemic Drugs Products Offered 12.4.5 GlaxoSmithKline Recent Development 12.5 Merck & Co 12.5.1 Merck & Co Corporation Information 12.5.2 Merck & Co Description and Business Overview 12.5.3 Merck & Co Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.5.4 Merck & Co Oral Hypoglycemic Drugs Products Offered 12.5.5 Merck & Co Recent Development 12.6 Eli Lilly 12.6.1 Eli Lilly Corporation Information 12.6.2 Eli Lilly Description and Business Overview 12.6.3 Eli Lilly Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.6.4 Eli Lilly Oral Hypoglycemic Drugs Products Offered 12.6.5 Eli Lilly Recent Development 12.7 Sanofi 12.7.1 Sanofi Corporation Information 12.7.2 Sanofi Description and Business Overview 12.7.3 Sanofi Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.7.4 Sanofi Oral Hypoglycemic Drugs Products Offered 12.7.5 Sanofi Recent Development 12.8 Takeda Pharmaceuticals 12.8.1 Takeda Pharmaceuticals Corporation Information 12.8.2 Takeda Pharmaceuticals Description and Business Overview 12.8.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.8.4 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Products Offered 12.8.5 Takeda Pharmaceuticals Recent Development 12.9 Novo Nordisk 12.9.1 Novo Nordisk Corporation Information 12.9.2 Novo Nordisk Description and Business Overview 12.9.3 Novo Nordisk Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.9.4 Novo Nordisk Oral Hypoglycemic Drugs Products Offered 12.9.5 Novo Nordisk Recent Development 12.10 Servier Laboratories 12.10.1 Servier Laboratories Corporation Information 12.10.2 Servier Laboratories Description and Business Overview 12.10.3 Servier Laboratories Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.10.4 Servier Laboratories Oral Hypoglycemic Drugs Products Offered 12.10.5 Servier Laboratories Recent Development 12.11 Pfizer 12.11.1 Pfizer Corporation Information 12.11.2 Pfizer Description and Business Overview 12.11.3 Pfizer Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.11.4 Pfizer Oral Hypoglycemic Drugs Products Offered 12.11.5 Pfizer Recent Development 12.12 Bristol-Myers Squibb 12.12.1 Bristol-Myers Squibb Corporation Information 12.12.2 Bristol-Myers Squibb Description and Business Overview 12.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2016-2021) 12.12.4 Bristol-Myers Squibb Products Offered 12.12.5 Bristol-Myers Squibb Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Oral Hypoglycemic Drugs Industry Trends 13.2 Oral Hypoglycemic Drugs Market Drivers 13.3 Oral Hypoglycemic Drugs Market Challenges 13.4 Oral Hypoglycemic Drugs Market Restraints 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Oral Hypoglycemic Drugs Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

List of Tables Table 1. Global Oral Hypoglycemic Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million) Table 2. Major Manufacturers of Sulfonylureas (SU) Table 3. Major Manufacturers of Double Guanidine Table 4. Major Manufacturers of Glucosidase Inhibitor Table 5. Major Manufacturers of Insulin Synergist Table 6. Global Oral Hypoglycemic Drugs Market Size Growth Rate by Application (2021-2027) & (K Units) Table 7. Global Oral Hypoglycemic Drugs Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027 Table 8. Global Oral Hypoglycemic Drugs Sales by Regions (2016-2021) & (K Units) Table 9. Global Oral Hypoglycemic Drugs Sales Market Share by Regions (2016-2021) Table 10. Global Oral Hypoglycemic Drugs Revenue by Regions (2016-2021) & (US$ Million) Table 11. Global Oral Hypoglycemic Drugs Sales Forecast by Region (2022-2027) & (K Units) Table 12. Global Oral Hypoglycemic Drugs Sales Market Share Forecast by Region (2022-2027) Table 13. Global Oral Hypoglycemic Drugs Revenue Forecast by Region (2022-2027) & (US$ Million) Table 14. Global Oral Hypoglycemic Drugs Revenue Market Share Forecast by Region (2022-2027) Table 15. Global Oral Hypoglycemic Drugs Sales by Manufacturers (2016-2021) (K Units) Table 16. Global Oral Hypoglycemic Drugs Sales Share by Manufacturers (2016-2021) Table 17. Ranking of Global Top Oral Hypoglycemic Drugs Manufacturers by Revenue (US$ Million) in 2020 Table 18. Oral Hypoglycemic Drugs Revenue by Manufacturers (2016-2021) (US$ Million) Table 19. Oral Hypoglycemic Drugs Revenue Share by Manufacturers (2016-2021) Table 20. Global Oral Hypoglycemic Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021) Table 21. Global Oral Hypoglycemic Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Hypoglycemic Drugs as of 2020) Table 22. Key Manufacturers Oral Hypoglycemic Drugs Price (2016-2021) (US$/Unit) Table 23. Oral Hypoglycemic Drugs Manufacturers Manufacturing Base Distribution and Headquarters Table 24. Manufacturers Oral Hypoglycemic Drugs Product Type Table 25. Date of International Manufacturers Enter into Oral Hypoglycemic Drugs Market Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans Table 27. Global Oral Hypoglycemic Drugs Sales by Type (2016-2021) (K Units) Table 28. Global Oral Hypoglycemic Drugs Sales Share by Type (2016-2021) Table 29. Global Oral Hypoglycemic Drugs Revenue by Type (2016-2021) (US$ Million) Table 30. Global Oral Hypoglycemic Drugs Revenue Share by Type (2016-2021) Table 31. Oral Hypoglycemic Drugs Average Selling Price (ASP) by Type (2016-2021) & (US$/Unit) Table 32. Global Oral Hypoglycemic Drugs Sales Forecast by Type (2022-2027) & (K Units) Table 33. Global Oral Hypoglycemic Drugs Sales Market Share Forecast by Type (2022-2027) Table 34. Global Oral Hypoglycemic Drugs Revenue Forecast V (2022-2027) & (US$ Million) Table 35. Global Oral Hypoglycemic Drugs Revenue Market Share Forecast by Type (2022-2027) Table 36. Global Oral Hypoglycemic Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) & (US$/Unit) Table 37. Global Oral Hypoglycemic Drugs Sales by Application (2016-2021) (K Units) Table 38. Global Oral Hypoglycemic Drugs Sales Share by Application (2016-2021) Table 39. Global Oral Hypoglycemic Drugs Revenue by Application (2016-2021) (US$ Million) Table 40. Global Oral Hypoglycemic Drugs Revenue Share by Application (2016-2021) Table 41. Oral Hypoglycemic Drugs Average Selling Price (ASP) by Application (2016-2021) & (US$/Unit) Table 42. Global Oral Hypoglycemic Drugs Sales Forecast by Application (2022-2027) & (K Units) Table 43. Global Oral Hypoglycemic Drugs Sales Market Share Forecast by Application (2022-2027) Table 44. Global Oral Hypoglycemic Drugs Revenue Forecast by Application (2022-2027) & (US$ Million) Table 45. Global Oral Hypoglycemic Drugs Revenue Market Share Forecast by Application (2022-2027) Table 46. Global Oral Hypoglycemic Drugs Average Selling Price (ASP) Forecast by Application (2022-2027) & (US$/Unit) Table 47. Japan Oral Hypoglycemic Drugs Sales (K Units) of Key Companies (2016-2021) Table 48. Japan Oral Hypoglycemic Drugs Sales Share by Company (2016-2021) Table 49. Japan Oral Hypoglycemic Drugs Revenue (US$ Million) by Company (2016-2021) Table 50. Japan Oral Hypoglycemic Drugs Revenue Share by Company (2016-2021) Table 51. Japan Oral Hypoglycemic Drugs Sales (K Units) by Type (2016-2021) Table 52. Japan Oral Hypoglycemic Drugs Sales Share by Type (2016-2021) Table 53. Japan Oral Hypoglycemic Drugs Revenue (US$ Million) Market Share by Type (2016-2021) Table 54. Japan Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2016-2021) Table 55. Japan Oral Hypoglycemic Drugs Sales (K Units) by Type (2022-2027) Table 56. Japan Oral Hypoglycemic Drugs Sales Share by Type (2022-2027) Table 57. Japan Oral Hypoglycemic Drugs Revenue (US$ Million) Market Share by Type (2022-2027) Table 58. Japan Oral Hypoglycemic Drugs Revenue Share by Type (2022-2027) Table 59. Japan Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2022-2027) Table 60. Japan Oral Hypoglycemic Drugs Sales (K Units) by Application (2016-2021) Table 61. Japan Oral Hypoglycemic Drugs Sales Share by Application (2016-2021) Table 62. Japan Oral Hypoglycemic Drugs Revenue (US$ Million) Market Share by Application (2016-2021) Table 63. Japan Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2016-2021) Table 64. Japan Oral Hypoglycemic Drugs Sales (K Units) by Application (2022-2027) Table 65. Japan Oral Hypoglycemic Drugs Sales Share by Application (2022-2027) Table 66. Japan Oral Hypoglycemic Drugs Revenue (US$ Million) Market Share by Application (2022-2027) Table 67. Japan Oral Hypoglycemic Drugs Revenue Share by Application (2022-2027) Table 68. Japan Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2022-2027) Table 69. North America Oral Hypoglycemic Drugs Sales by Country (2016-2021) & (K Units) Table 70. North America Oral Hypoglycemic Drugs Sales Market Share by Country (2016-2021) Table 71. North America Oral Hypoglycemic Drugs Revenue by Country (2016-2021) & (US$ Million) Table 72. North America Oral Hypoglycemic Drugs Revenue Market Share by Country (2016-2021) Table 73. Asia Pacific Oral Hypoglycemic Drugs Sales by Region (2016-2021) & (K Units) Table 74. Asia Pacific Oral Hypoglycemic Drugs Sales Market Share by Region (2016-2021) Table 75. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region (2016-2021) & (US$ Million) Table 76. Asia Pacific Oral Hypoglycemic Drugs Revenue Market Share by Region (2016-2021) Table 77. Europe Oral Hypoglycemic Drugs Sales by Country (2016-2021) & (K Units) Table 78. Europe Oral Hypoglycemic Drugs Sales Market Share by Country (2016-2021) Table 79. Europe Oral Hypoglycemic Drugs Revenue by Country (2016-2021) & (US$ Million) Table 80. Europe Oral Hypoglycemic Drugs Revenue Market Share by Country (2016-2021) Table 81. Latin America Oral Hypoglycemic Drugs Sales by Country (2016-2021) & (K Units) Table 82. Latin America Oral Hypoglycemic Drugs Sales Market Share by Country (2016-2021) Table 83. Latin Americaa Oral Hypoglycemic Drugs Revenue by Country (2016-2021) & (US$ Million) Table 84. Latin America Oral Hypoglycemic Drugs Revenue Market Share by Country (2016-2021) Table 85. Middle East and Africa Oral Hypoglycemic Drugs Sales by Country (2016-2021) & (K Units) Table 86. Middle East and Africa Oral Hypoglycemic Drugs Sales Market Share by Country (2016-2021) Table 87. Middle East and Africa Oral Hypoglycemic Drugs Revenue by Country (2016-2021) & (US$ Million) Table 88. Middle East and Africa Oral Hypoglycemic Drugs Revenue Market Share by Country (2016-2021) Table 89. Pfizer Corporation Information Table 90. Pfizer Description and Business Overview Table 91. Pfizer Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 92. Pfizer Oral Hypoglycemic Drugs Product Table 93. Pfizer Recent Development Table 94. AstraZeneca Corporation Information Table 95. AstraZeneca Description and Business Overview Table 96. AstraZeneca Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 97. AstraZeneca Product Table 98. AstraZeneca Recent Development Table 99. Johnson & Johnson Corporation Information Table 100. Johnson & Johnson Description and Business Overview Table 101. Johnson & Johnson Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 102. Johnson & Johnson Product Table 103. Johnson & Johnson Recent Development Table 104. GlaxoSmithKline Corporation Information Table 105. GlaxoSmithKline Description and Business Overview Table 106. GlaxoSmithKline Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 107. GlaxoSmithKline Product Table 108. GlaxoSmithKline Recent Development Table 109. Merck & Co Corporation Information Table 110. Merck & Co Description and Business Overview Table 111. Merck & Co Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 112. Merck & Co Product Table 113. Merck & Co Recent Development Table 114. Eli Lilly Corporation Information Table 115. Eli Lilly Description and Business Overview Table 116. Eli Lilly Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 117. Eli Lilly Product Table 118. Eli Lilly Recent Development Table 119. Sanofi Corporation Information Table 120. Sanofi Description and Business Overview Table 121. Sanofi Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 122. Sanofi Product Table 123. Sanofi Recent Development Table 124. Takeda Pharmaceuticals Corporation Information Table 125. Takeda Pharmaceuticals Description and Business Overview Table 126. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 127. Takeda Pharmaceuticals Product Table 128. Takeda Pharmaceuticals Recent Development Table 129. Novo Nordisk Corporation Information Table 130. Novo Nordisk Description and Business Overview Table 131. Novo Nordisk Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 132. Novo Nordisk Product Table 133. Novo Nordisk Recent Development Table 134. Servier Laboratories Corporation Information Table 135. Servier Laboratories Description and Business Overview Table 136. Servier Laboratories Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 137. Servier Laboratories Product Table 138. Servier Laboratories Recent Development Table 139. Boehringer Ingelheim Corporation Information Table 140. Boehringer Ingelheim Description and Business Overview Table 141. Boehringer Ingelheim Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 142. Boehringer Ingelheim Product Table 143. Boehringer Ingelheim Recent Development Table 144. Bristol-Myers Squibb Corporation Information Table 145. Bristol-Myers Squibb Description and Business Overview Table 146. Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021) Table 147. Bristol-Myers Squibb Product Table 148. Bristol-Myers Squibb Recent Development Table 149. Oral Hypoglycemic Drugs Market Trends Table 150. Oral Hypoglycemic Drugs Market Drivers Table 151. Oral Hypoglycemic Drugs Market Challenges Table 152. Oral Hypoglycemic Drugs Market Restraints Table 153. Oral Hypoglycemic Drugs Customers List Table 154. Oral Hypoglycemic Drugs Distributors List Table 155. Research Programs/Design for This Report Table 156. Key Data Information from Secondary Sources Table 157. Key Data Information from Primary Sources List of Figures Figure 1. Oral Hypoglycemic Drugs Product Picture Figure 2. Global Oral Hypoglycemic Drugs Sales Market Share by Type in 2020 & 2027 Figure 3. Sulfonylureas (SU) Product Picture Figure 4. Double Guanidine Product Picture Figure 5. Glucosidase Inhibitor Product Picture Figure 6. Insulin Synergist Product Picture Figure 7. Global Oral Hypoglycemic Drugs Sales Market Share by Application in 2020 & 2027 Figure 8. Hospital Figure 9. Clinic Figure 10. Others Figure 11. Oral Hypoglycemic Drugs Report Years Considered Figure 12. Global Oral Hypoglycemic Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027 Figure 13. Global Oral Hypoglycemic Drugs Market Size 2016-2027 (US$ Million) Figure 14. Global Oral Hypoglycemic Drugs Sales 2016-2027 (K Units) Figure 15. Global Oral Hypoglycemic Drugs Market Size Market Share by Region: 2021 Versus 2027 Figure 16. Global Oral Hypoglycemic Drugs Sales Market Share by Region (2016-2021) Figure 17. Global Oral Hypoglycemic Drugs Sales Market Share by Region in 2020 Figure 18. Global Oral Hypoglycemic Drugs Revenue Market Share by Region (2016-2021) Figure 19. Global Oral Hypoglycemic Drugs Revenue Market Share by Region in 2020 Figure 20. Global Oral Hypoglycemic Drugs Sales Share by Manufacturer in 2020 Figure 21. The Top 10 and 5 Players Market Share by Oral Hypoglycemic Drugs Revenue in 2020 Figure 22. Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 23. Global Oral Hypoglycemic Drugs Sales Market Share by Type (2016-2021) Figure 24. Global Oral Hypoglycemic Drugs Sales Market Share by Type in 2020 Figure 25. Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2016-2021) Figure 26. Global Oral Hypoglycemic Drugs Revenue Market Share by Type in 2020 Figure 27. Global Oral Hypoglycemic Drugs Sales Market Share by Application (2016-2021) Figure 28. Global Oral Hypoglycemic Drugs Sales Market Share by Application in 2020 Figure 29. Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2016-2021) Figure 30. Global Oral Hypoglycemic Drugs Revenue Market Share by Application in 2020 Figure 31. Japan Oral Hypoglycemic Drugs Sales Growth Rate 2016-2027 (K Units) Figure 32. Japan Oral Hypoglycemic Drugs Revenue Growth Rate 2016-2027 (US$ Million) Figure 33. Japan Oral Hypoglycemic Drugs Market Share in Global Market 2016-2027 Figure 34. Japan 5 and 10 Largest Oral Hypoglycemic Drugs Players Market Share by Revenue in Oral Hypoglycemic Drugs in 2020 Figure 35. Japan Oral Hypoglycemic Drugs Revenue Share by Type (2016-2021) Figure 36. Japan Oral Hypoglycemic Drugs Revenue Growth Rate by Type in 2016 & 2020 Figure 37. Japan Oral Hypoglycemic Drugs Revenue Share by Application (2016-2021) Figure 38. Japan Oral Hypoglycemic Drugs Revenue Growth Rate by Application in 2016 & 2020 Figure 39. North America Oral Hypoglycemic Drugs Sales Growth Rate 2016-2021 (K Units) Figure 40. North America Oral Hypoglycemic Drugs Revenue Growth Rate 2016-2021 (US$ Million) Figure 41. North America Oral Hypoglycemic Drugs Sales Market Share by Country in 2020 Figure 42. North America Oral Hypoglycemic Drugs Revenue Market Share by Country in 2020 Figure 43. U.S. Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 44. U.S. Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Canada Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 46. Canada Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Europe Oral Hypoglycemic Drugs Sales Growth Rate 2016-2021 (K Units) Figure 48. Europe Oral Hypoglycemic Drugs Revenue Growth Rate 2016-2021 (US$ Million) Figure 49. Europe Oral Hypoglycemic Drugs Sales Market Share by Country in 2020 Figure 50. Europe Oral Hypoglycemic Drugs Revenue Market Share by Country in 2020 Figure 51. Germany Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 52. Germany Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 53. France Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 54. France Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 55. U.K. Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 56. U.K. Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 57. Italy Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 58. Italy Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 59. Russia Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 60. Russia Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 61. Asia Pacific Oral Hypoglycemic Drugs Sales Growth Rate 2016-2021 (K Units) Figure 62. Asia Pacific Oral Hypoglycemic Drugs Revenue Growth Rate 2016-2021 (US$ Million) Figure 63. Asia Pacific Oral Hypoglycemic Drugs Sales Market Share by Region in 2020 Figure 64. Asia Pacific Oral Hypoglycemic Drugs Revenue Market Share by Region in 2020 Figure 65. China Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 66. China Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 67. Japan Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 68. Japan Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 69. South Korea Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 70. South Korea Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 71. India Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 72. India Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 73. Australia Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 74. Australia Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 75. Taiwan Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 76. Taiwan Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 77. Indonesia Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 78. Indonesia Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 79. Thailand Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 80. Thailand Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 81. Malaysia Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 82. Malaysia Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 83. Philippines Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 84. Philippines Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 85. Vietnam Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 86. Vietnam Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 87. Latin America Oral Hypoglycemic Drugs Sales Growth Rate 2016-2021 (K Units) Figure 88. Latin America Oral Hypoglycemic Drugs Revenue Growth Rate 2016-2021 (US$ Million) Figure 89. Latin America Oral Hypoglycemic Drugs Sales Market Share by Country in 2020 Figure 90. Latin America Oral Hypoglycemic Drugs Revenue Market Share by Country in 2020 Figure 91. Mexico Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 92. Mexico Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 93. Brazil Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 94. Brazil Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 95. Argentina Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 96. Argentina Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 97. Middle East and Africa Oral Hypoglycemic Drugs Sales Growth Rate 2016-2021 (K Units) Figure 98. Middle East and Africa Oral Hypoglycemic Drugs Revenue Growth Rate 2016-2021 (US$ Million) Figure 99. Middle East and Africa Oral Hypoglycemic Drugs Sales Market Share by Country in 2020 Figure 100. Middle East and Africa Oral Hypoglycemic Drugs Revenue Market Share by Country in 2020 Figure 101. Turkey Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 102. Turkey Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 103. Saudi Arabia Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 104. Saudi Arabia Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 105. UAE Oral Hypoglycemic Drugs Sales Growth Rate (2016-2021) (K Units) Figure 106. UAE Oral Hypoglycemic Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 107. Oral Hypoglycemic Drugs Value Chain Figure 108. Channels of Distribution Figure 109. Distributors Profiles Figure 110. Bottom-up and Top-down Approaches for This Report Figure 111. Data Triangulation Figure 112. Key Executives Interviewed

Pfizer AstraZeneca Johnson & Johnson GlaxoSmithKline Merck & Co Eli Lilly Sanofi Takeda Pharmaceuticals Novo Nordisk Servier Laboratories Boehringer Ingelheim Bristol-Myers Squibb